Feed/Companies/Latigo Biotherapeutics

Latigo Biotherapeutics

As of 14 Oct 2026, Latigo Biotherapeutics has raised $150M across 1 verified round on record; latest: $150 million Series B led by Blue Owl, announced 17 Mar 2025.

BUILT ON

Visit site

Latigo is a clinical-stage biopharmaceutical company developing innovative non-opioid pain medicines.

latigobio.comLinkedIn

LATEST ROUND

Series B

$150M · 2025-03-17

RAISED ON RECORD · USD

$150M

across 1 verified round

INVESTORS

1 lead

SOURCES

from 1 publisher

Rounds

[ 1

Feed/Companies

Company

Every round on record, with the sources behind each and the investors on them.

BUILT ON

Series B

$150M · 2025-03-17

[ HISTORY ]

led by Blue Owl

Round	Amount	Announced	Lead	Buzz
Series B [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it.	$150M	2025-03-17	Blue Owl	No recent discussion
1 source [ VERIFIED · CORRECTED ] read against 1 source The source provides a Thousand Oaks, Calif. dateline, but does not explicitly state the company's headquarters.

Latigo Biotherapeutics

Rounds

Company

Rounds

Sources

Profile

Investors

Latigo Biotherapeutics

Rounds

Profile

Sources

Series B$150M2025-03-171 source

Investors

Series B$150M2025-03-1713 investors